INVEX Therapeutics (ASX:IXC) to Issue 45 Million Shares as Acquisition Consideration

Aditi Sarkar

26 October 2026 03:11 PM AEDT

INVEX Therapeutics (ASX:IXC) to Issue 45 Million Shares as Acquisition Consideration

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

INVEX proposes to issue up to 45,000,000 ordinary shares at an estimated A$0.08 per share.
A further 91,250,000 performance rights across three classes are proposed.
All securities are consideration for the acquisition of Rekover Therapeutics.
Shareholder approval is required, with a meeting proposed for 4 December 2026.

INVEX Therapeutics Ltd (ASX:IXC) has lodged an Appendix 3B outlining a proposed issue of securities as consideration for its acquisition of Rekover Therapeutics. The notice, dated 26 October 2026, sets out a proposed issue of ordinary shares and three new classes of performance rights, subject to shareholder approval.

Details of the Proposed Securities

INVEX plans to issue up to 45,000,000 fully paid ordinary shares at an estimated A$0.08 per share. The company also proposes to issue 91,250,000 performance rights, comprising 22,812,500 Class A rights expiring on 15 December 2030, 45,625,000 Class B rights expiring on 15 June 2031 and 22,812,500 Class C rights expiring on 15 December 2031.

Each performance right has an exercise price of A$0.0001 and will convert into one ordinary share once vested and exercised. The proposed issue date is 14 December 2026.

Purpose of the Issue

All of the securities are being issued as consideration for the acquisition of Rekover Therapeutics. None of the shares are being issued for cash, and no lead manager or underwriter has been appointed.

The full terms of the performance rights are expected to be set out in a Notice of General Meeting in early November 2026. INVEX has directed investors to its separate announcement of 26 October 2026 for further details on the acquisition.

Approvals and Escrow

The issue requires shareholder approval under Listing Rule 7.1, with a meeting proposed for 4 December 2026. No related parties under Listing Rule 10.11 are participating in the issue.

Consideration shares issued to certain vendors will be subject to voluntary escrow for 12 months from completion of the acquisition.

Key Takeaways

INVEX is using shares and performance rights to fund its acquisition of Rekover Therapeutics.
The performance rights structure links part of the consideration to future milestones.
Shareholder approval on 4 December 2026 is the key next step.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.